http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104459146-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2013-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104459146-B |
| titleOfInvention | A kind of new application of DC-SIGNR |
| abstract | The invention provides the application in the product of preparation discriminating, diagnosis, auxiliary diagnosis, examination and/or auxiliary examination colorectal cancer and transfer case thereof of the DC-SIGNR albumen。The present invention is by DC-SIGNR protein concentration in ELISA experiment detection serum in patients with colorectal and normal human serum, found that DC-SIGNR protein concentration is significantly higher than normal person (P < 0.0001) in serum in patients with colorectal；In colorectal cancer transfer patients serum, DC-SIGNR protein concentration is higher than the colorectal cancer patients (P=0.0002) that transfer does not occur。Meanwhile, again colon cancer and rectal cancer patient are further analyzed respectively, it was demonstrated that in patients serum, DC-SIGNR protein concentration levels all has value in various degree for diagnosis and the Differential Diagnosis whether shifted of colon cancer and rectal cancer。Therefore, the present invention has huge social meaning and economic worth。 |
| priorityDate | 2013-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.